1-Methylcyclodecane-1-carbonitrile | 35664-90-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1-Methylcyclodecane-1-carbonitrile
• CAS: 35664-90-5
• 化学式: C₁₂H₂₁N
• 分子量: 179.305
• InChiKey: PZPARRUDGABATL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  23.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  Cyclodecanecarbonitrile 、 硫酸二甲酯 生成 1-Methylcyclodecane-1-carbonitrile
  参考文献：
  名称：

  Lorenz,P. et al., Chemische Berichte, 1971, vol. 104, p. 3429 - 3455

  摘要：

  DOI：

文献信息

• NOVEL ANTIFUNGAL AGENT CONTAINING HETEROCYCLIC COMPOUND
  申请人：NAKAMOTO Kazutaka

  公开号：US20110195999A1

  公开（公告）日：2011-08-11

  The present invention provides an antifungal agent represented by the formula: wherein A 1 represents a 3-pyridyl group which may have a substituent, a quinolyl group which may have a substituent, or the like; X 1 represents a group represented by the formula —NH—C(═O)—, a group represented by the formula —C(═O)—NH—, or the like; E represents a furyl group, a thienyl group, a pyrrolyl group, a phenyl group, a pyridyl group, a tetrazolyl group, a thiazolyl group or a pyrazolyl group; with the proviso that A 1 may have 1 to 3 substituents, and E has one or two substituents.

  本发明提供一种抗真菌剂，其化学式如下： 其中，A1代表3-吡啶基，可以有取代基，喹啉基，也可以有取代基等；X1代表由公式—NH—C（═O）—，由公式—C（═O）—NH—等表示的基团；E代表呋喃基，噻吩基，吡咯基，苯基，吡啶基，四唑基，噻唑基或吡唑基；但要求A1可能有1到3个取代基，E有1或2个取代基。
• 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER
  申请人：Boston Biomedical, Inc.

  公开号：US20190241569A1

  公开（公告）日：2019-08-08

  The invention provides novel inhibitors of cancer stem cells as well as cancer stem cell pathway kinase and other related kinases, pharmaceutical compositions and uses thereof in the treatment of cancer or a related disorder in a mammal, and methods of making such compounds and compositions.
• UBE2K MODULATORS AND METHODS FOR THEIR USE
  申请人：Berg LLC

  公开号：US20220002255A1

  公开（公告）日：2022-01-06

  Provided are compounds of Formula (I): and pharmaceutically acceptable salts and compositions thereof, which are useful for treating conditions associated with modulation of UBE2K.